StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
69
This month
2
This week
1
This year
5
Publishing Date
2024 - 03 - 18
1
2024 - 01 - 29
1
2024 - 01 - 09
1
2023 - 12 - 22
1
2023 - 10 - 18
1
2023 - 10 - 12
1
2023 - 09 - 26
1
2023 - 09 - 20
1
2023 - 09 - 11
1
2023 - 08 - 16
1
2023 - 06 - 28
1
2023 - 06 - 05
1
2023 - 05 - 17
1
2023 - 05 - 11
1
2023 - 05 - 08
1
2023 - 05 - 04
1
2023 - 05 - 03
1
2023 - 04 - 24
1
2023 - 04 - 17
2
2022 - 10 - 27
2
2022 - 10 - 18
1
2022 - 09 - 22
1
2022 - 09 - 16
1
2022 - 09 - 15
2
2022 - 09 - 12
1
2022 - 09 - 06
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 06 - 20
1
2022 - 06 - 07
2
2022 - 05 - 16
1
2022 - 05 - 05
1
2022 - 04 - 14
1
2022 - 04 - 11
1
2021 - 12 - 13
1
2021 - 11 - 29
1
2021 - 11 - 19
1
2021 - 10 - 13
1
2021 - 10 - 08
1
2021 - 10 - 04
2
2021 - 09 - 29
2
2021 - 09 - 09
1
2021 - 09 - 07
1
2021 - 08 - 11
1
2021 - 08 - 09
1
2021 - 07 - 28
1
2021 - 07 - 21
1
2021 - 07 - 13
1
2021 - 07 - 01
1
2021 - 06 - 25
1
2021 - 06 - 22
2
2021 - 06 - 15
1
2021 - 06 - 11
1
2021 - 06 - 09
1
2021 - 06 - 04
1
2021 - 05 - 25
1
2021 - 05 - 11
1
2021 - 04 - 26
1
2021 - 04 - 20
1
2021 - 03 - 24
1
Sector
Commercial services
1
Communications
2
Finance
1
Health technology
55
Manufacturing
4
Professional, scientific, and technical services
2
Tags
Agreement
2
Alliances
3
Application
2
Biopharma
2
Biotech
2
Biotechnology
3
Cancer
4
Car-t
9
Cel
3
Cell
12
Chmp
2
Collaboration
6
Commercialization
2
Covid
5
Designation
6
Disease
3
Drug
5
Europe
2
Events
2
Fda
8
Genetown
3
Global
2
Grant
2
Granted
3
Her2
2
Her2-
2
Inb-400
2
Leukemia
2
License
3
Mb-106
2
Meeting
2
N/a
33
Orphan drug
2
Patent
2
Ph-762
2
Pharm-country
3
Pharmaceutical
4
Pharmaceuticals
2
Phase 1
4
Phase 2
3
Phase 3
2
Platform
2
Positive
7
Potential
5
Pre-clinical
3
Preclinical
8
Probody
2
Program
3
Regulatory
2
Research
14
Results
2
Review
2
Sars-cov-2
3
Study
6
T-cell
41
Therapeutics
9
Therapy
20
Treatment
17
Trial
9
Vaccine
4
Entities
2seventy bio, inc.
1
Abbott laboratories
1
Actinium pharmaceuticals, inc.
1
Adaptimmune therapeutics plc
1
Adaptive biotechnologies corporation
1
Adc therapeutics sa
1
Adicet bio, inc.
1
Allovir, inc.
3
Autolus therapeutics plc
5
Bristol-myers squibb company
3
Caribou biosciences inc
1
Coya therapeutics, inc.
1
Cytomed therapeutics pte. ltd.
1
Cytomx therapeutics, inc.
2
Enlivex therapeutics ltd.
1
Fate therapeutics, inc.
1
Fortress biotech, inc.
2
Genocea biosciences, inc.
1
Gilead sciences, inc.
2
Gracell biotechnologies inc - adr
1
Gritstone oncology, inc.
1
Ibio, inc.
1
Immatics n.v.
1
Immune therapeutics, inc.
1
Immuron limited
1
In8bio inc
4
Intellia therapeutics, inc.
1
Johnson & johnson
3
Kiromic biopharma, inc.
1
Kymera therapeutics, inc.
1
Lyell immunopharma inc
1
Mustang bio, inc.
2
Novartis ag
1
Oncolytics biotech inc.
1
Orange
2
Phio pharmaceuticals corp.
4
Poseida therapeutics, inc.
2
Precision biosciences, inc.
2
Sanofi
1
Soligenix, inc.
6
Sqz biotechnologies company
2
Tg therapeutics, inc.
1
The blackstone group inc.
1
Tscan therapeutics inc
1
Vaxart, inc.
1
Vir biotechnology, inc.
1
Viracta therapeutics inc
2
Xencor, inc.
1
Symbols
ABT
1
ACET
1
ADAP
1
ADCT
1
ADPT
1
ALVR
3
ATNM
1
AUTL
5
BMY
3
BX
1
COYA
1
CRBU
1
CTMX
2
DTIL
2
ENLV
1
FATE
1
FBIO
2
FNCTF
2
GDTC
1
GILD
2
GNCA
1
GRCL
1
GRTS
1
IBIO
1
IMRN
1
IMTX
1
IMUN
1
INAB
4
JNJ
3
KRBP
1
KYMR
1
LYEL
1
MBIO
2
NTLA
1
NVS
1
NVSEF
1
ONCY
1
PHIO
4
PSTX
2
SNGX
6
SNY
1
SQZ
2
TCRX
1
TGTX
1
TSVT
1
VIR
1
VIRX
2
VXRT
1
XNCR
1
Exchanges
Amex
2
Nasdaq
60
Nyse
11
Crawled Date
2024 - 03 - 18
1
2024 - 01 - 29
1
2024 - 01 - 09
1
2023 - 12 - 22
1
2023 - 10 - 18
1
2023 - 10 - 12
1
2023 - 09 - 26
1
2023 - 09 - 20
1
2023 - 09 - 11
1
2023 - 08 - 16
1
2023 - 06 - 28
1
2023 - 06 - 05
1
2023 - 05 - 17
1
2023 - 05 - 11
1
2023 - 05 - 08
1
2023 - 05 - 04
1
2023 - 05 - 03
1
2023 - 04 - 24
1
2023 - 04 - 17
2
2022 - 10 - 27
2
2022 - 10 - 18
1
2022 - 09 - 22
1
2022 - 09 - 16
1
2022 - 09 - 15
2
2022 - 09 - 12
1
2022 - 09 - 06
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 06 - 20
1
2022 - 06 - 07
2
2022 - 05 - 16
1
2022 - 05 - 05
1
2022 - 04 - 14
1
2022 - 04 - 11
1
2021 - 12 - 13
1
2021 - 11 - 29
1
2021 - 11 - 19
1
2021 - 10 - 13
1
2021 - 10 - 08
1
2021 - 10 - 04
2
2021 - 09 - 29
2
2021 - 09 - 09
1
2021 - 09 - 07
1
2021 - 08 - 11
1
2021 - 08 - 09
1
2021 - 07 - 28
1
2021 - 07 - 21
1
2021 - 07 - 13
1
2021 - 07 - 01
1
2021 - 06 - 25
1
2021 - 06 - 22
2
2021 - 06 - 15
1
2021 - 06 - 11
1
2021 - 06 - 09
1
2021 - 06 - 04
1
2021 - 05 - 25
1
2021 - 05 - 11
1
2021 - 04 - 26
1
2021 - 04 - 20
1
2021 - 03 - 24
1
Crawled Time
00:00
17
00:20
3
01:00
14
02:00
3
06:00
5
07:00
4
08:00
7
09:00
4
10:00
1
10:41
1
11:00
21
11:02
1
11:33
1
12:00
69
12:01
1
12:03
1
12:07
1
12:15
7
12:20
13
12:25
1
12:30
15
12:39
1
12:43
1
13:00
68
13:01
2
13:03
2
13:12
1
13:15
9
13:20
13
13:30
8
13:59
2
14:00
56
14:01
1
14:15
4
14:20
6
14:30
8
15:00
30
15:01
1
15:06
1
15:15
3
15:20
5
15:30
5
16:00
18
16:20
10
17:00
9
18:00
17
18:42
1
19:00
15
20:00
20
20:20
5
21:00
20
21:03
2
22:00
19
23:00
15
23:02
1
Source
investors.phiopharma.com
3
www.biospace.com
36
www.globenewswire.com
23
www.immatics.com
1
www.prnewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
t-cell
crawled time :
12:00
save search
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published:
2024-04-15
(Crawled : 12:00)
- globenewswire.com
VIRX
|
$0.912
27.59%
21.62%
190K
|
Manufacturing
|
-39.42%
|
O:
-12.71%
H:
0.97%
C:
-24.27%
t-cell
positive
topline
trial
therapeutics
results
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published:
2024-04-03
(Crawled : 12:00)
- globenewswire.com
CTMX
|
$1.765
-5.11%
-5.38%
590K
|
Health Technology
|
-13.08%
|
O:
-0.47%
H:
2.35%
C:
0.94%
probody
candidate
t-cell
collaboration
therapeutics
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published:
2024-03-18
(Crawled : 12:00)
- globenewswire.com
CTMX
|
$1.765
-5.11%
-5.38%
590K
|
Health Technology
|
-10.14%
|
O:
0.97%
H:
0.48%
C:
-3.35%
probody
collaboration
therapeutics
milestone
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
Published:
2024-01-29
(Crawled : 12:00)
- globenewswire.com
GDTC
|
$2.12
4.72%
3.1K
|
|
-42.86%
|
O:
2.17%
H:
0.0%
C:
-3.97%
patent
granted
cell
technology
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published:
2024-01-09
(Crawled : 12:00)
- globenewswire.com
TGTX
|
$13.825
-1.25%
-1.27%
3.1M
|
Health Technology
|
-34.27%
|
O:
-8.22%
H:
9.05%
C:
7.47%
DTIL
|
$11.5
-10.65%
-11.91%
220K
|
Health Technology
|
3133.67%
|
O:
10.0%
H:
14.23%
C:
0.09%
cd19
license
cell
treatment
global
commercialization
program
therapeutics
agreement
therapy
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Published:
2023-12-22
(Crawled : 12:00)
- globenewswire.com
ALVR
|
$0.7521
2.34%
2.29%
570K
|
Health Technology
|
-68.46%
|
O:
-67.32%
H:
7.03%
C:
0.51%
cell
program
therapy
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Published:
2023-10-18
(Crawled : 12:00)
- globenewswire.com
CRBU
|
$3.92
-2.24%
-2.3%
2M
|
Health Technology
|
-7.39%
|
O:
-0.69%
H:
0.0%
C:
-5.35%
cb-012
fda
cell
treatment
clearance
application
car-t
leukemia
therapy
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Published:
2023-10-12
(Crawled : 12:00)
- globenewswire.com
INAB
|
$1.02
4.05%
140K
|
|
-1.97%
|
O:
1.0%
H:
0.0%
C:
-5.94%
inb-100
inb-400
cell
treatment
trial
potential
therapy
glioblastoma
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
Published:
2023-09-26
(Crawled : 12:00)
- globenewswire.com
INAB
|
$1.02
4.05%
140K
|
|
-17.62%
|
O:
3.36%
H:
3.25%
C:
-6.5%
day
cell
city
research
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Published:
2023-09-20
(Crawled : 12:00)
- globenewswire.com
VIR
|
$8.255
-1.26%
-1.27%
760K
|
Health Technology
|
-15.13%
|
O:
-0.3%
H:
0.61%
C:
-4.58%
vir-1388
vaccine
cell
hiv
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Published:
2023-09-11
(Crawled : 12:00)
- globenewswire.com
LYEL
|
$2.385
-1.04%
640K
|
Professional, Scientific, and T...
|
32.42%
|
O:
4.4%
H:
7.88%
C:
5.26%
t-cell
cell
therapy
platform
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Published:
2023-08-16
(Crawled : 12:00)
- globenewswire.com
MBIO
|
$0.352
1.68%
120K
|
Health Technology
|
-90.89%
|
O:
5.53%
H:
0.0%
C:
-9.23%
FBIO
|
$1.79
1.7%
1.68%
240K
|
Health Technology
|
259.18%
|
O:
1372.45%
H:
1.87%
C:
-3.85%
mb-106
cell
ongoing
car-t
trial
therapy
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
Published:
2023-06-28
(Crawled : 12:00)
- globenewswire.com
VIRX
|
$0.912
27.59%
21.62%
190K
|
Manufacturing
|
-50.01%
|
O:
1.4%
H:
8.91%
C:
4.14%
t-cell
expansion
trial
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
Published:
2023-06-05
(Crawled : 12:00)
- biospace.com/
COYA
|
$8.2
0.37%
0.37%
75K
|
|
78.77%
|
O:
-2.19%
H:
5.59%
C:
-6.04%
disease
alzheimer’s
system
therapeutics
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Published:
2023-05-17
(Crawled : 12:00)
- globenewswire.com
INAB
|
$1.02
4.05%
140K
|
|
-63.28%
|
O:
0.37%
H:
5.33%
C:
3.73%
cancer
promise
show
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published:
2023-05-11
(Crawled : 12:00)
- biospace.com/
SNGX
|
$0.4963
5.15%
4.9%
4M
|
Health Technology
|
-42.19%
|
O:
3.5%
H:
0.58%
C:
-8.88%
fda
t-cell
review
treatment
meeting
study
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
Published:
2023-05-08
(Crawled : 12:00)
- globenewswire.com
ENLV
|
$1.47
1.38%
1.36%
390K
|
Health Technology
|
-47.08%
|
O:
2.92%
H:
6.38%
C:
6.03%
patent
t-cell
therapy
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published:
2023-05-04
(Crawled : 12:00)
- biospace.com/
SNGX
|
$0.4963
5.15%
4.9%
4M
|
Health Technology
|
-66.76%
|
O:
150.7%
H:
17.98%
C:
-35.96%
t-cell
positive
treatment
results
study
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Published:
2023-05-03
(Crawled : 12:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-29.13%
|
O:
0.34%
H:
0.6%
C:
-2.47%
breyanzi
approval
one
cell
therapy
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published:
2023-04-24
(Crawled : 12:00)
- prnewswire.com
SNGX
|
$0.4963
5.15%
4.9%
4M
|
Health Technology
|
-68.95%
|
O:
10.53%
H:
0.0%
C:
-8.33%
fda
t-cell
review
treatment
meeting
study
← Previous
1
2
3
4
Next →
Gainers vs Losers
55%
45%
Top 10 Gainers
INVO
|
$2.78
265.79%
200M
|
Health Technology
SINT
|
$0.0366
59.83%
460M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
1.9M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
800K
|
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
BCAN
|
$1.13
28.86%
22.4%
8.2M
|
Construction
Your saved searches
Save your searches and get alerts when important news are released.